IRIS CKD Staging Simulator

Feline/canine chronic kidney disease staged by creatinine and SDMA per IRIS guidelines.

Current Stage

—

—

IRIS Stage

—

Kidney Function Left

—

SDMA Detection Value

—

Management

—

Creatinine level (mg/dL)1.0

SDMA level (μg/dL)14

Functioning nephron

Lost/sclerotic nephron

Creatinine gauge

SDMA gauge

Proteinuria/BP substage marker

Scroll for details

Stage 1 — Early Kidney Disease Before Azotemia Appears

Placeholder: early kidney damage exists before blood creatinine rises.

<1.6: Creatinine (mg/dL, placeholder range)
<18: SDMA (μg/dL, placeholder range)
~0-25%: Nephrons lost (placeholder estimate)
None/mild: Clinical signs (placeholder summary)

Detecting disease before azotemia

Placeholder: imaging, urinalysis, and SDMA can flag risk early.

Stage 2 — Mild Azotemia With Reduced Renal Reserve

Placeholder: creatinine climbs mildly as functioning nephrons decline.

1.6-2.8: Creatinine (mg/dL, placeholder range)
18-25: SDMA (μg/dL, placeholder range)
~25-50%: Nephrons lost (placeholder estimate)
Subtle: Clinical signs (placeholder summary)

Managing early mild azotemia

Placeholder: diet change and monitoring begin at this stage.

Stage 3 — Moderate Azotemia and Emerging Clinical Signs

Placeholder: moderate nephron loss brings noticeable clinical signs.

2.9-5.0: Creatinine (mg/dL, placeholder range)
26-38: SDMA (μg/dL, placeholder range)
~50-75%: Nephrons lost (placeholder estimate)
Moderate: Clinical signs (placeholder summary)

Interventions at moderate stage

Placeholder: phosphate binders and renal diet become important.

Stage 4 — Severe Azotemia and Uremic Risk

Placeholder: severe nephron loss risks uremic crisis without care.

>5.0: Creatinine (mg/dL, placeholder range)
>38: SDMA (μg/dL, placeholder range)
~75-95%: Nephrons lost (placeholder estimate)
Severe: Clinical signs (placeholder summary)

Intensive management at severe stage

Placeholder: hospitalization and dialysis may be considered.

Substaging by Proteinuria and Blood Pressure

Placeholder: proteinuria and hypertension refine prognosis within stage.

<0.2 / 0.2-0.4 / >0.4: UPC ratio (placeholder cutoffs)
<150 / 150-179 / ≥180: Systolic BP (placeholder cutoffs)
Low/Med/High: Risk tiers (placeholder summary)
Frequent: Rechecks (placeholder guidance)

Why substaging matters

Placeholder: proteinuria and blood pressure predict progression risk.

Placeholder: substage guides added therapy beyond IRIS stage alone.